首页> 美国卫生研究院文献>Journal of the International AIDS Society >Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy

【2h】

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy

机译：在意大利接受艾滋病毒感染者中使用定剂量联合恩曲他滨/利比韦林/替诺福韦（Eviplera）的决定因素

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionEmtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is licensed in Europe for use only in ARV-naïve patients with a viral load (VL) ≤100,000 copies/mL.

机译：简介恩曲他滨/利比韦林/替诺福韦（EVP）是抗逆转录病毒药物（ARV）的固定剂量组合，于2011年11月获得欧洲药品管理局的批准，于2013年2月在意大利推出。它是每日一次的单一片剂，并在欧洲，仅用于病毒载量（VL）≤100,000拷贝/ mL的无ARV的患者。

著录项

期刊名称 Journal of the International AIDS Society
作者
Alessandro Cozzi-Lepri; Sergio Lo Caputo; Franco Maggiolo; Andrea Antinori; Adriana Ammassari; Giulia Marchetti; Claudio Mastroianni; Andrea Gori; Giovanni Di Perri; Gioacchino Angarano; Alessia Carbone; Antonella dArminio Monforte;
展开▼
作者单位

展开▼
年(卷),期 2014(17),4Suppl 3
年度 2014
页码 19775
总页数 2
原文格式 PDF
正文语种
中图分类免疫学 ; 病毒传染病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy [J] . Alessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, Journal of the International Aids Society . 2014 ,第4Suppla3期

机译：在意大利接受艾滋病毒感染者中使用固定剂量联合恩曲他滨/利比韦林/替诺福韦（Eviplera）的决定因素
2. Skeletal muscle toxicity associated with emtricitabine/rilpivirine/ tenofovir fixed-dose combination: A case report [J] . BewleyS., NguyenL.B.L., WelbournA., AIDS . 2014 ,第13期

机译：恩曲他滨/利比韦林/替诺福韦固定剂量联合使用引起的骨骼肌毒性：一例报告
3. Safety and efficacy of fixed‐dose combination rilpivirine‐tenofovir‐emtricitabine (RPV/TDF/FTC) in treatment‐experienced patients infected with HIV‐1 [J] . M Cevik, S Sonecha, M Nelson Journal of the International Aids Society . 2012 ,第Suppla1期

机译：固定剂量利比韦林-替诺福韦-恩曲他滨（RPV / TDF / FTC）固定剂量对治疗经验丰富的HIV-1感染患者的安全性和有效性
4. Determinants status of patient after receiving treatment at Intensive Care Unit: A case study in Johor Bahru [C] . Bin Shafi Muhammad Ammar, Bin Rusiman Mohd Saifullah, Che Yusof Nur Syaliza Hanim International Conference on Computer, Communications, and Control Technology . 2014

机译：重症监护室接受治疗后患者的决定因素状态：新山的个案研究
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study [O] . Karin Neukam, Nuria Espinosa, Antonio Collado, -1

机译：Rilpivirine / Emtricitabine / Tenofovir富马酸替诺福韦酯固定剂量单片方案对活动性丙型肝炎病毒感染HIV的患者的肝安全性：hEPAtic研究
7. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy [O] . Alessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, 2014

机译：在意大利接受艾滋病毒感染者中使用定剂量联合恩曲他滨/利比韦林/替诺福韦（Eviplera）的决定因素

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy

摘要

著录项

相似文献

相关主题

期刊订阅